info@seagull-health.com
SeagullHealth
语言:
search
new
What are the side effects of Encorafenib?
501
Article source: Seagull Pharmacy
Jun 18, 2025

Encorafenib in combination with bimetinib is indicated for the treatment of adult patients with metastatic NSCLC detected by an FDA-approved test with a BRAF V600E mutation. The approval builds on positive results from the Phase II PHAROS trial, which demonstrated significant therapeutic activity in both treatment-naïve and treatment-experienced patients with Encorafenib in combination with bimetinib.

What are the side effects of Encorafenib?

The side effects of Encorafenib involve multiple systems, and the symptoms and degree of response vary significantly between patients.

Adverse reactions of Encorafenib combined with bimetinib

When Encorafenib is combined with bimetinib, common adverse effects (≥25%) include fatigue, nausea, vomiting, abdominal pain, and arthralgia. These symptoms may have an impact on the patient's daily life.

Adverse reactions of Encorafenib combined with cetuximab treatment

In combination therapy with Encorafenib and cetuximab, patients may experience adverse reactions (≥25%) including fatigue, nausea, diarrhea, acneiform dermatitis, abdominal pain, decreased appetite, arthralgia, and rash. These reactions need to be of concern to both the physician and the patient.

Other possible side effects

In addition to the common side effects mentioned above, Encorafenib may also cause adverse effects in other systems, such as neurological reactions (such as headache, dizziness, etc.), cardiovascular system reactions (such as high blood pressure, etc.), and hematologic reactions (such as bleeding problems, etc.). During the use of Encorafenib, patients should pay close attention to their physical condition and seek medical attention if there is any abnormality.

Understanding the side effects of Encorafenib is essential to ensure patient safety. Next, we'll explore how to deal with these side effects.

What should I do if I have side effects from taking Encorafenib?

In the face of the side effects of Encorafenib, patients and doctors need to take proactive measures to deal with it.

Inform your doctor promptly

Once side effects occur, patients should inform their doctor immediately so that the doctor can evaluate and take appropriate treatment measures in time. Your doctor may adjust your medication regimen or treat your symptoms based on your specific situation.

Symptomatic treatment

Doctors may treat different side effects differently. For example, nausea and vomiting can be relieved with anti-nausea medications; Diarrhoea can be treated with antidiarrheal drugs or dietary modifications.

Maintain good habits

During treatment, patients should maintain good lifestyle habits, including eating a reasonable diet, exercising moderately, and getting enough sleep. These measures help to strengthen the body's immunity and mitigate the effects of side effects.

Understanding how to deal with the side effects of Encorafenib is essential to improve the quality of life for patients. Next, we'll explore the storage considerations for Encorafenib.

What do I need to pay attention to when storing Encorafenib?

Proper storage conditions are an important part of ensuring the efficacy of a drug.

Storage temperature

Encorafenib should be stored at room temperature between 20°C and 25°C. Temperatures that are too high or too low can affect the effectiveness of the drug.

Store in a dark, sealed and dry place

To protect the drug from light, moisture, and other external factors, Encorafenib should be stored in a dark, sealed, dry environment. Avoid exposing the drug to extreme conditions such as heat, sun exposure, or freezing.

Check the status of your medications regularly

Before using Encorafenib, patients should check the status of the drug regularly to ensure that it has not deteriorated or damaged. If you notice any abnormalities in the drug, such as discoloration, deformation, or mold, you should stop using it immediately and consult a doctor.

Correct storage conditions are an important guarantee to ensure the efficacy of Encorafenib. Patients should strictly adhere to storage requirements during the use of Encorafenib. Understanding the side effects of drugs and coping strategies is also an important part of ensuring the safety of patients.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Encorafenib(BRAFTOVI)
Encorafenib(BRAFTOVI)
For the treatment of melanoma, colorectal cancer (CRC), and non-small cell lung...
WeChat Scan
Free Inquiry
Recommended Articles
What are the precautions for Encorafenib?
Encorafenib is an oral small molecule BRAF inhibitor developed by ARRAY BIOPHARMA in the United States and licensed by Pierre Fabre of France to obtain the exclusive commercialization rights in the Ch...
How effective is Encorafenib treatment?
As a targeted therapeutic drug, Encorafenib has shown significant efficacy in the treatment of diseases with positive gene mutations in recent years. However, the evaluation of drug efficacy is not on...
What is the daily dose of Encorafenib?
Encorafenib, as a targeted therapeutic drug, is mainly used to treat melanin placeholding and colorectal cell lesions. It provides patients with new therapeutic options by inhibiting the growth and sp...
Is Encorafenib an oral drug?
Encorafenib is a targeted drug used to treat specific gene mutations, mainly for the treatment of melanopathy and colorectal masses. Its correct application and dosage are essential to ensure the effe...
Adverse effects of Encorafenib(BRAFTOVI)
Encorafenib (BRAFTOVI) is a therapeutic drug that targets BRAF gene mutations, which may cause a series of adverse reactions while bringing significant efficacy. Adverse effects of Encorafenib (BRAFTO...
What are the side effects of Encorafenib?
Encorafenib IS AN ORAL SMALL MOLECULE BRAF INHIBITOR DEVELOPED BY ARRAY BIOPHARMA IN THE UNITED STATES. In the Chinese market, the French company Pierre Fabre has obtained an exclusive commercializati...
Binimetinib(Mektovi) Uses, Usage
Binimetinib (Mektovi) is a targeted drug for the treatment of BRAF-V600E or V600K mutation-positive unresectable or metastatic melanoma. It inhibits the growth and spread of diseased cells by inhibiti...
The efficacy of Binimetinib(Mektovi)
Binimetinib(Mektovi), also known as Binimetinib, is a targeted drug for the treatment of BRAF-V600E or V600K mutation-positive unresectable or metastatic melanoma. It inhibits the growth and spread of...
Related Articles
How to Use Encorafenib (Braftovi)
Encorafenib (Braftovi) is a kinase inhibitor that was first approved in the United States in 2018 for the treatment of advanced malignant tumors harboring specific BRAF gene mutations.How to Use Encor...
Indications of Encorafenib (Braftovi)
Encorafenib (Braftovi) is an oral kinase inhibitor that first received approval for marketing from the U.S. Food and Drug Administration (FDA) in 2018. Specifically designed to treat malignant tumors ...
How to Purchase Encorafenib (Braftovi)
Encorafenib (Braftovi) is an important kinase inhibitor drug used for the treatment of unresectable or metastatic melanoma, metastatic colorectal cancer, and metastatic non-small cell lung cancer with...
What are the side effects of Encorafenib?
Encorafenib IS AN ORAL SMALL MOLECULE BRAF INHIBITOR DEVELOPED BY ARRAY BIOPHARMA IN THE UNITED STATES. In the Chinese market, the French company Pierre Fabre has obtained an exclusive commercializati...
Adverse effects of Encorafenib(BRAFTOVI)
Encorafenib (BRAFTOVI) is a therapeutic drug that targets BRAF gene mutations, which may cause a series of adverse reactions while bringing significant efficacy. Adverse effects of Encorafenib (BRAFTO...
What are the side effects of Encorafenib?
Encorafenib in combination with bimetinib is indicated for the treatment of adult patients with metastatic NSCLC detected by an FDA-approved test with a BRAF V600E mutation. The approval builds on pos...
What are the precautions for Encorafenib?
Encorafenib is an oral small molecule BRAF inhibitor developed by ARRAY BIOPHARMA in the United States and licensed by Pierre Fabre of France to obtain the exclusive commercialization rights in the Ch...
How effective is Encorafenib treatment?
As a targeted therapeutic drug, Encorafenib has shown significant efficacy in the treatment of diseases with positive gene mutations in recent years. However, the evaluation of drug efficacy is not on...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved